Streetbeat News

Earnings

IRON

Disc Medicine (NASDAQ:IRON) reported a Q4 EPS of $(0.97), missing the consensus estimate of $(0.78) by 24.36%.

Portfolio Pulse from Happy Mohamed

March 21, 2024 | 12:11 pm

DHI

GOOGL

JBL

TPC

Notable insider sales were reported for Alphabet, Jabil, D.R. Horton, and Tutor Perini. These sales could indicate various strategic decisions by the insiders. Alphabet's CEO sold shares amidst news of a new Pixel feature. Jabil's revenue fell short of estimates, while D.R. Horton is set to release financial results. Tutor Perini received a price target update from UBS.

Portfolio Pulse from Avi Kapoor

March 21, 2024 | 12:10 pm

ASO

Academy Sports (ASO) reported a Q4 comparable sales decline of 3.6%. This indicates a decrease in sales compared to the same period in the previous year, which could impact investor sentiment and the company's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:08 pm

TSLA

Gary Black, Future Fund Managing Partner, remains optimistic about Tesla Inc's Cybertruck, predicting it to be a key earnings catalyst by 2025. Black estimates Tesla currently produces 400 Cybertrucks weekly, potentially increasing to 1,000 by Q4 2023, aiming for 30,000 deliveries this year. He projects a profit of $15,000 per Cybertruck in 2023, contributing $0.1/share to EPS, and anticipates 100,000 deliveries in 2025 at $20,000 profit each, adding $0.5/share to EPS. Despite these projections, Black's delivery estimates are lower than Musk's target of 250,000 Cybertrucks by 2025. Black maintains a $250 price target for Tesla, above its current price, and expects the Cybertruck to positively impact Tesla's entire lineup, similar to the Model Y launch.

Portfolio Pulse from Anan Ashraf

March 21, 2024 | 12:08 pm

LIQT

LiqTech International projects its Q1 FY24 sales to be between $4.1 million and $4.3 million.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:07 pm

ABOS

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) announced it will present Phase 1 INTERCEPT-AD study data of sabirnetug (ACU193) for Alzheimer's at the AAN Annual Meeting. The study shows sabirnetug's engagement with toxic AβOs, indicating progress in Alzheimer's treatment. Acumen plans to initiate a Phase 2 trial in the first half of 2024. Sabirnetug has received Fast Track designation from the FDA for early Alzheimer's treatment.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:07 pm

ASO

Academy Sports (ASO) projects its FY24 comparable sales to range between a decrease of 4% and an increase of 1%.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:07 pm

LIQT

LiqTech International reported its full-year sales at $18.0 million, marking an increase from the previous year's $16.0 million.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:07 pm

CURI

CuriosityStream Inc. (NASDAQ:CURI) shares surged premarket after reporting Q4 FY23 results. Despite missing revenue expectations with $14.8 million against a $15.8 million consensus, the company saw a significant increase in gross profit to $6.7 million from $1.4 million a year ago. Expenses fell 32% Y/Y to $11.4 million, and the adjusted EBITDA loss improved to $(3.4) million from $(13.6) million. EPS loss of $(0.09) beat the $(0.15) consensus. The company declared its first quarterly cash dividend of $0.025 per share and expects Q1 revenue of $11.5 million-$12.5 million, below the consensus of $15.8 million, but anticipates positive adjusted free cash flow.

Portfolio Pulse from Lekha Gupta

March 21, 2024 | 12:07 pm

LABP

Landos Biopharma (NASDAQ:LABP) reported a Q4 EPS loss of $(0.99), missing the consensus estimate of $(0.91) by 8.79%. However, this represents a 23.85% improvement over the $(1.30) loss per share from the same period last year. The company also reported a cash balance of $37.5M.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:06 pm